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enhances insulin sensitivity by improving glucose utilization
in tissues like liver or muscle. Metformin inhibits respiration,
and the decrease in cellular energy activates the AMP-
activated protein kinase that in turn switches on catabolic
pathways. Moreover, metformin increases lipolysis and
b-oxidation in white adipose tissue, thereby reducing the
triglyceride stores. The uncoupling proteins (UCPs) are
transporters that lower the efficiency of mitochondrial
oxidative phosphorylation. UCP2 is thought to protect
against oxidative stress although, alternatively, it could play
an energy dissipation role. The aim of this work was to analyse
the involvement of UCP2 on the effects of metformin in
white adipocytes. We studied the effect of this drug inJournal of Endocrinology (2008) 199, 33–40
0022–0795/08/0199–033 q 2008 Society for Endocrinology Printed in Greatdifferentiating 3T3-L1 adipocytes and found that metformin
causes oxidative stress since it increases the levels of reactive
oxygen species (ROS) and lowers the aconitase activity.
Variations in UCP2 protein levels parallel those of ROS.
Metformin also increases lipolysis in these cells although only
when the levels of ROS and UCP2 have decreased. Hence,
UCP2 does not appear to be needed to facilitate fatty acid
oxidation. Furthermore, treatment of C57BL/6 mice with
metformin also augmented the levels of UCP2 in epididymal
white adipose tissue. We conclude that metformin treatment
leads to the overexpression of UCP2 in adipocytes to
minimize the oxidative stress that is probably due to the
inhibition of respiration caused by the drug.
Journal of Endocrinology (2008) 199, 33–40Introduction
The uncoupling proteins (UCPs) are carriers that belong to
the protein superfamily constituted by the metabolite
transporters of the mitochondrial inner membrane. In
mammals, there are five genes that encode proteins considered
to be UCP1 (Ledesma et al. 2002, Krauss et al. 2005). UCP1 is
present in brown adipose tissue and it is the onlymember of the
family whose physiological function and regulation have been
firmly established. UCP1 is a proton transporter activated by
fatty acids and it is involved in non-shivering thermogenesis
(Rial & Gonzalez-Barroso 2001). UCP2 is ubiquitously
expressed while UCP3 is only found in skeletal muscle and
brown adipose tissue. UCP4 (currently known as SLC25A27)
and UCP5 (currently known as SLC25A14) are predomi-
nantly expressed in the nervous system. The physiological roles
of UCP2 and UCP3 are not fully understood (Cannon et al.
2006, Be´zaire et al. 2007). According to their family name,
these proteins should lower the efficiency of themitochondrial
oxidative phosphorylation by allowing a regulated discharge of
the proton gradient.
The superoxide anion, the hydroxyl radical or hydrogen
peroxide are highly reactive molecules that are collectively
termed reactive oxygen species (ROS). ROS can chemically
modify membranes, proteins or DNA and therefore highROS levels can lead to a variety of pathologies (Halliwell &
Gutteridge 1999, Lenaz 2001). Thus, in resting (state 4)
conditions, when oxygen consumption is low and the proton-
motive force (pmf) is high, the rate of superoxide formation is
at its maximum. However, an increase in the respiratory rate,
due to an increase in ATP demand for example, will diminish
the formation of ROS (Brookes 2005).
UCP2 is upregulated in a number of physiological
situations where there is oxidative stress. The mitochondrial
respiratory chain is probably the most important source
of superoxide and its rate of formation depends on respiratory
activity. UCP2 could contribute to the protection against
oxidative damage by increasing the membrane proton
conductance and accelerating respiration. In fact, the first
phenotype described for the UCP2 knock-out mouse was an
increased resistance to infection by toxoplasma, which
correlated with higher levels of ROS in macrophages
(Arsenijevic et al. 2000). Steatotic livers have also chronically
elevated levels of ROS and a higher expression of UCP2
(Evans et al. 2008). The increased expression of UCP2
and diminished susceptibility to oxidative stress in certain
drug-resistant tumour cell lines are also noteworthy (Harper
et al. 2002).
Diabetes is a disease characterized by a chronic elevation of
the circulating glucose levels, which has toxic effects on aDOI: 10.1677/JOE-08-0278
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and nervous systems, etc. Elevated glucose levels are also toxic
for b-cells, which progressively lose their ability to secrete
insulin thereby worsening the situation (Newsholme et al.
2007). It is now widely accepted that hyperglycaemia causes
oxidative stress and that b-cells are particularly susceptible to
oxidative damage (Green et al. 2004). In these cells, UCP2
appears to play a dual role. While UCP2 could be part of the
antioxidant defence system, as in other cells (Krauss et al.
2005, Affourtit & Brand 2008), there is also evidence that
UCP2 may participate in the control of insulin secretion.
Indeed, UCP2-deficient mice are hypoglycaemic due to
increased glucose-stimulated insulin secretion associated with
higher islet ATP levels (Zhang et al. 2001), while insulin levels
are low in models of UCP2 overexpression (Chan et al. 1999,
2001, Hong et al. 2001). Thus, variations in UCP2 expression
and/or activity could contribute to b-cell dysfunction and to
the development of diabetes (Affourtit & Brand 2008).
Metformin (dimethylbiguanidine) is widely used to treat
type 2 non-insulin-dependent diabetes mellitus (Bailey et al.
1996, Kirpichnikov et al. 2002). It is an insulin-sensitizing
agent that has beneficial effects not only on glycaemic levels
but also in the cardiovascular system. However, the mode of
action of metformin has yet to be fully established. In muscle,
liver and endothelial cells, the metabolic changes induced by
metformin appear to be mediated by the AMP-activated
protein kinase (AMPK). AMPK acts as a sensor of the cellular
energy status, being switched on by an increased ATP demand
or by processes that interfere with ATP production like
ischaemia. The activated form of AMPK switches on
catabolic pathways while switching off ATP-consuming
processes (Hardie et al. 2006). It has been reported that
metformin binds to complex I of the mitochondrial
respiratory chain and this could in part explain how this
drug acts (Owen et al. 2000). The inhibition of complex I
would cause a decrease in energy supply that would in turn
lead to a higher AMP/ATP ratio, and the concomitant
activation of AMPK.
In white adipose tissue, metformin also stimulates catabolic
pathways through the activation of AMPK, reducing the
triglyceride stores as reflected by the smaller size of the
adipocytes (Lenhard et al. 1997, Huypens et al. 2005). These
effects are achieved through an increase in lipolysis and
b-oxidation, which would imply that there is no release of
fatty acids and that they are oxidized within the adipocyte. In
this respect, it must be emphasized that metformin also causes
an increase in mitochondrial mass (Lenhard et al. 1997). This
situation would be similar to that caused by leptin, a hormone
involved in the control of energy balance that increases energy
expenditure and suppresses appetite (Ahima & Flier 2000).
Hyperleptinaemia decreases the mRNA levels of lipogenic
enzymes while it increases those involved in lipolysis (Zhou
et al 1997, Ceddia et al. 2000), and the fatty acids released are
oxidized inside the adipocyte instead of being exported to
other tissues (Wang et al. 1999). Interestingly, UCP2
expression is also induced under those conditions. TheseJournal of Endocrinology (2008) 199, 33–40effects of leptin require an increase in the expression of the
peroxisomal proliferation-activated receptor a, a well-known
upregulator of mitochondrial biogenesis (Lee et al. 2002).
The aim of the present study was to determine whether
UCP2 is involved in the action of metformin on white
adipocytes. The working hypothesis was that UCP2 could be
overexpressed either to uncouple respiration to facilitate fatty
acid oxidation or to minimize the generation of ROS that
would be due to the inhibition of complex I. The data
obtained demonstrate that metformin causes oxidative stress
in the adipocyte cell line 3T3-L1 and that as a result UCP2 is
overexpressed as part of the antioxidant defence response.Materials and Methods
Materials
All materials were obtained from Sigma–Aldrich unless
otherwise stated. Cell culture media, antibiotics and bovine
serum were from Gibco/Invitrogen. The UCP2 antibody was
from Santa Cruz Biotechnology (Santa Cruz, CA, USA)
while the antibody against porin was from Sigma–Aldrich.Experimental animals and treatments
Adult C57BL/6 male mice (14 weeks old) weighing 25–30 g
were used in this study. Twenty mice were maintained at
22 8Cwith a 12 h light:12 h darkness cycle, and with access to
food and water ad libitum. Ten mice were injected
intraperitoneally daily with a dose of metformin
(250 mg/kg of body weight) for 3 days, while ten control
mice received 0.9% saline. On the last day, the mice were
killed 1 h after the injection. Liver, spleen, epididymal white
adipose tissue and hind limb skeletal muscle were recovered
from the mice and immediately frozen in liquid nitrogen. All
procedures were performed in accordance with the European
regulations for the protection of animals used for experi-
mental and other scientific purposes.Cell culture and differentiation
3T3-L1 mouse embryo fibroblasts were obtained from the
American Type Culture Collection (Mansassas, VA, USA).
Cells were cultured in a humidified atmosphere at 37 8C and
5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% (v/v) heat-inactivated bovine serum supple-
mented with penicillin (100 U/ml) and streptomycin
(100 mg/ml). When the cells reached confluence, the culture
medium was switched to DMEM supplemented with 10%
(v/v) heat-inactivated foetal bovine serum (FBS) plus
antibiotics. Two days after they reached confluence (day 2),
1 mM 3-isobutyl-1-methylxanthine (IBMX), 1 mM insulin
and 1 mM dexamethasone were added to the medium to
induce their differentiation to adipocytes. After 3 days (day 5),
this medium was replaced by fresh DMEM/10% FBSwww.endocrinology-journals.org
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subjected to the different treatments in DMEM/10% FBS.
Preparation of mitochondria-enriched extracts from mouse tissues
Mitochondria-enriched fractions were prepared from liver,
spleen, epididymal white adipose tissue and hind limb skeletal
muscle. Liver, spleen and white adipose tissue were homogen-
ized in 250 mM sucrose, 1 mM EDTA and 10 mM Tris–HCl
(pH 7.4) plus 0.1% (v/v) of the mammalian protease inhibitor
cocktail from Sigma–Aldrich. Homogenates were centrifuged
at 10 000 g for 10 min at 4 8C, and the pellet obtained was
resuspended and centrifuged at 750 g for 10 min. The
supernatant was collected and spun at 10 000 g for 20 min,
and the final pellet was resuspended in 10–30 ml of the isolation
buffer. Themitochondrial-enriched fractions frommusclewere
prepared after mincing the tissue in 100 mM sucrose, 46 mM
KCl, 2 mM EDTA and 10 mM Tris–HCl (pH 7.4) supple-
mented with the protease inhibitor cocktail. The tissue was
homogenized and spun at 500 g for 10 min, and the supernatant
was collected and spun for 10 min at 10 000 g. The pellet was
finally resuspended in 10–30 ml of the same buffer.
PBS-washed 3T3-L1 adipocytes were suspended in a buffer
containing 250 mM sucrose, 0.1 mM EDTA and 5 mM
HEPES (pH 7.4) plus 0.1% (v/v) of the protease inhibitor
cocktail. Cells were subjected to three freeze/thaw cycles and
centrifuged at 750 g for 10 min, the supernatant collected and
centrifuged at 10 000 g for 20 min. The pellet obtained was
resuspended in 10–20 ml of the same buffer. In all cases, the
protein concentration was determined by the bicinchoninic
acid assay using BSA as standard.
Oil red O staining and cell mass determination
Differentiation of 3T3-L1 cells was assessed by Oil red O
staining on day 12. Cells were washed with cold PBS and
fixed in 4% paraformaldehyde for 1 h. Dishes were rinsed
with 60% isopropanol, dried and the cells were stained for
10 min with 0.2%Oil red O in isopropanol/water (6:4). After
extensive washes with distilled water, the Oil red O was
eluted by adding 100% isopropanol and the dye was quantified
by measuring the absorbance at 500 nm (Ramı´rez-Zacarı´as
et al. 1992). Cell mass was assessed from the protein recovered
from individual 100 mm diameter Petri dishes. Cells were
washed with PBS and scrapped from the dishes, centrifuged at
2000 g for 5 min and resuspended in 1 ml 250 mM sucrose,
0.1 mM EDTA and 5 mM HEPES (pH 7.4) plus 0.1% (v/v)
of the protease inhibitor cocktail. Protein was determined by
the bicinchoninic acid assay.
Western blot analysis
About 30–60 mg of the mitochondrial extracts were resolved
by SDS-PAGE and then transferred to membranes that were
probed with either an anti-UCP2 antibody or a mouse anti-
porin antibody used as a loading control. The immunoblots
were developed by enhanced chemiluminescence (GEwww.endocrinology-journals.orgHealthcare, Little Chalfont, UK), and the band intensity
was recorded using the CCD camera of a Fujifilm LAS-3000
analyzer and quantified with the Fujifilm MultiGauge
programme, (Fuji Photo Film GmbH, Du¨sseldorf, Germany).
Aconitase activity
Aconitase activity was determined using the in-gel assay
described by Tong et al. (2003). Adipocytes were lysed in a
buffer containing 0.08% digitonin, 210 mM mannitol,
70 mM sucrose, 4 mM HEPES (pH 7.2) and 0.1% of Sigma’s
protease inhibitor cocktail, for 10 min at 4 8C. The lysate was
centrifuged at 750 g for 10 min, and the supernatant was
collected and then centrifuged again at 7000 g for 10 min.
The pellet was resuspended in a buffer containing 20 mM
Tris–HCl (pH 8.8), 137 mMNaCl, 10% v/v glycerol and 1%
(v/v) Triton X-100, and the samples resolved by PAGE under
non-denaturing conditions. The gel was incubated in the
darkness at 37 8C for 30 min in a buffer containing 1.2 mM
methylthiazoletetrazolium, 0.3 mM phenazine methosul-
phate and 5 U/ml isocitrate dehydrogenase. The enzyme
activity was then recorded using the CCD camera of a
Fujifilm LAS-3000 analyzer and quantified with the Fujifilm
MultiGauge programme.
Analysis of the levels of ROS
Adipocytes were trypsinized and resuspended in DMEM
containing 1% FBS at a concentration of one million cells per
ml. Cells were incubated in the presence of 5 mM
dihydroethidium (DHE) for 30 min at 37 8C in the darkness.
Samples were washed twice in the same medium and the
fluorescence analysed using an EPICS XL flow cytometer.
Lipolysis assay
Lipolysis was estimated from the release of glycerol using
Wieland’s method (Wieland 1974). After each treatment
50 ml of the culture medium were mixed with 950 ml reaction
mixture containing 1.23 mM ATP, 0.56 mM NAD, 5 U/ml
glycerophosphate dehydrogenase, 350 U/ml glycerokinase,
1 M hydrazine hydrate, 0.2 M glycine and 2 mMMgCl2. The
samples were incubated for 40 min at room temperature and
the absorbance at 340 nm was then determined.
Statistical analysis
All results are shown as the meanGS.E.M. of data from at least
three independent experiments. The statistical significance of
the differences was calculated using Student’s t-test, and values
of P!0.05 were accepted as statistically significant.Results
Adipocyte differentiation and metformin treatments
Conditions were established to induce the differentiation of
the 3T3-L1 cells from fibroblastic progenitors to matureJournal of Endocrinology (2008) 199, 33–40
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growth for 3 days (from day 2 to 5) in medium supplemented
with IBMX, insulin and dexamethasone followed by another
2 days in the presence of insulin. Between day 9 and 12, more
than 90% of the fibroblasts had differentiated into mature
adipocytes with a multilocular distribution of the triglyceride
droplets. On day 7 of differentiation, the cultures were
divided into four groups: control, insulin (1 mM), metformin
(4 mM) and metformin plus insulin. The cells were collected
and characterized on days 7 (prior to any treatment), 9 and 12.
On day 12, dishes treated with metformin presented lower
cell mass as revealed from the total protein recovered from the
dishes (Fig. 1E). Additionally, metformin-treated cells
appeared to be less differentiated than control or insulin-
treated ones (Fig. 1). The effect of metformin was also
reflected in a lower triglyceride content, as revealed by Oil
red O staining (Fig. 1F). The presence of insulin in the
metformin-treated cells improved the degree of differen-
tiation. When metformin was added at the beginning of the
differentiation protocol, adipogenesis was markedly inhibited
(data not shown).Figure 1 Effect of metformin and insulin on the differentiation of
3T3-L1 cells after 12 days of differentiation. Representative Oil red
O staining of the cultured cells. From day 7, cells were maintained
in culture medium DMEM plus 10% FBS under the following
conditions: (A) control cells with no further additions, (B) medium
supplemented with 1 mM insulin, (C) 4 mM metformin, (D) 1 mM
insulin plus 4 mM metformin, (E) cell mass expressed as the protein
recovered from individual Petri dishes and (F) quantification of Oil
red O staining. Results are expressed as meansGS.E.M. of at least
three independent experiments. Conditions are Control; Ins, 1 mM
insulin; Met, 4 mM metformin; MCI, 1 mM insulin plus 4 mM
metformin. *P!0.05 of the experimental condition versus the
control cells.Metformin causes oxidative stress in 3T3-L1 adipocytes
If metformin binds to complex I of the respiratory chain and
inhibits electron transfer, an increase in ROS production
would be expected. Thus, the action of metformin would
resemble that of rotenone. The ROS levels in 3T3-L1 cells
were measured with the fluorescent probe DHE and they
were compared with the values obtained in the presence of
rotenone as a reference (Fig. 2A). As expected, the addition of
rotenone to control cells produced a threefold increase in
DHE fluorescence. While the ROS levels did not vary in
control or insulin-treated cells, metformin treatment caused a
marked increase in ROS, which was most evident on day 9
when it almost reached the rotenone values. ROS damage was
assessed by measuring the activity of the mitochondrial
enzyme aconitase. Accordingly, while control or insulin-
treated cells showed almost constant aconitase activity during
the 5 days of treatment, the presence of metformin caused a
decrease close to 50% in the activity of this enzyme (Fig. 2B).Metformin causes an increase in UCP2 levels
Since many reports indicate that UCP2 is overexpressed when
oxidative stress increases, the expression of this protein was
examined. UCP2 expression is controlled at both the
transcriptional and translational levels and in several instances,
the variations in the mRNA and protein levels are not
correlated (Pecqueur et al. 2001). Therefore, we determined
the levels of UCP2 protein by immunoblotting in mito-
chondria-enriched extracts and found that the variations in
UCP2 levels paralleled those of ROS. Thus, while UCP2 was
barely detected in control adipocytes, the treatment with
metformin caused a marked increase in its expression that
peaked on day 9 (Fig. 2C and D). Insulin did not alter theJournal of Endocrinology (2008) 199, 33–40expression of UCP2. Interestingly, mRNA levels did not vary
under any of our experimental conditions (data not shown).UCP2 expression does not correlate with the lipolytic activity in
3T3-L1 adipocytes
The expression of UCP2 is sometimes linked to an increase in
fatty acid oxidation. Indeed, hyperleptinaemia induces
lipolysis and raises the levels of fatty acid oxidation enzymes,
as well as those of UCP2 (Zhou et al. 1997). We determined
the rate of lipolysis under our conditions by measuring the
release of glycerol into the medium. Differentiation led to an
increase in glycerol release on day 9, which was similar under
the four conditions studied (Fig. 3). However, on day 12,
metformin-treated cells showed a 70% increase in lipolysiswww.endocrinology-journals.org
Figure 2 Metformin causes oxidative stress in differentiating 3T3-L1 cells. Effects of metformin and insulin in oxidative stress parameters
(A and B) and UCP2 protein levels (C and D) on days 9 and 12 of adipocyte differentiation. From day 7, cells were treated with either
1 mM insulin (Ins), 4 mM metformin (Met) or 1 mM insulin plus 4 mM metformin (MCI). Untreated cells were used as control (Cont).
(A) ROS levels measured by flow cytometry using the fluorescent probe DHE. (B) Aconitase activity. In (A) and (B), cells treated with
4 mM rotenone for 2 h were used as a reference. (C) Representative western blot for the expression of UCP2 under our experimental
conditions (top lane). The mitochondrial protein porin was used as loading control (bottom lane). (D) Variations in the UCP2 expression
levels. In all panels, data represent meansGS.E.M. of at least three independent experiments. *P!0.05 of the experimental condition
versus the corresponding control cells of the same day.
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Significantly, the presence of insulin moderated the effect of
metformin.Figure 3 Metformin induces lipolysis in differentiating 3T3-L1
adipocytes. Glycerol release was used as an index of lipolysis
during adipocyte differentiation under our experimental conditions.
From day 7 of differentiation, cells were treated with either 1 mM
insulin (Ins), 4 mM metformin (Met) or 1 mM insulin plus 4 mM
metformin (ICM). Untreated cells were used as control (Cont).
Values are presented as meansGS.E.M. of three to four independent
experiments, performed in duplicate. *P!0.05 of the experimental
condition versus the control cells of the same day.Metformin induces the expression of UCP2 in mouse white
adipose tissue
To investigate whether the effects of metformin in 3T3-L1
adipocytes could also be reproduced in vivo, C57BL/6 mice
were injected daily with doses of 250 mg metformin per kg
over 3 days. Mitochondria were isolated from tissues that
could be relevant for the antidiabetic activity of the drug such
as epididymal white adipose tissue, hind limb skeletal muscle
and liver. Spleen mitochondria were used as control since
UCP2 expression is known to be high (Pecqueur et al. 2001).
While UCP2 protein levels were low in white adipose tissue
from control animals, it increased markedly upon metformin
treatment (Fig. 4). UCP2 protein was undetectable in either
muscle or liver mitochondria from control mice or those
treated with metformin (data not shown).www.endocrinology-journals.org Journal of Endocrinology (2008) 199, 33–40
Figure 4 Metformin induces the expression of UCP2 in white
adipose tissue of C57BL/6 mice. Representative western blot of
UCP2 in mitochondria isolated from mice epididymal white
adipose tissue. UCP2 expression in spleen mitochondria from
control mice is shown as a reference. Ten mice were injected
intraperitoneally with a daily dose of 0.9% saline solution for 3 days
(C1, C2) while another ten mice were injected with metformin
250 mg/kg (M1, M2). Mitochondrial porin was used as loading
control (bottom lane).
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ROS are highly reactive molecules that, although they can
chemically damage cellular components, participate in the
maintenance of cellular redox homeostasis and in signal
transduction pathways (Droge 2002, Biswas et al. 2006). Cells
possess detoxification systems that protect them from the
harmful effects of ROS, both in the cytoplasm and in
mitochondria (Mate´s et al. 1999, Nordberg & Arner 2001).
Oxidative stress occurs when there is an excess of ROS, due to
an imbalance between its formation and degradation, which
not only causes cellular damage but also alters signalling
pathways. This disequilibrium is involved in or underlies a
variety of human pathologies like inflammation, ischaemia/
reperfusion injury, diabetes, atherosclerosis, neurodegenera-
tion or tumour formation (Halliwell & Gutteridge 1999,
Lenaz 2001).
Superoxide is produced in the cell by various enzyme
systems although the respiratory chain makes mitochondria
one of the major sources of ROS (Barja 1999, Turrens 2003).
Electron transfer at complexes I and III includes steps that
permit the monovalent reduction of oxygen to form the
superoxide radical. The rate of mitochondrial ROS formation
depends on the redox state of those sites, which in turn
depends on the magnitude of the pmf: the higher the pmf, the
lower the respiratory rate and the higher the rate of ROS
formation. Therefore, the induction of proton leakage
pathways to decrease the pmf is a means to diminish oxidative
stress (Brookes 2005). The involvement of UCP2 as a defence
mechanism against oxidative stress is well documented
although evidence is largely circumstantial. Thus, UCP2 is
induced under conditions of stress and its absence leads to the
increase in ROS formation (Arsenijevic et al. 2000).
Nevertheless, the physiological role of UCP2 remains
controversial. The upregulation of UCP2 induced by leptin,
when lipolysis and b-oxidation are also promoted, could
indicate that it is involved in energy dissipation (Zhou et al.
1997, Ceddia et al. 2000). This function would be similar to
that of UCP1 in brown adipose tissue where uncoupling
the oxidative phosphorylation converts the adipocytes intoJournal of Endocrinology (2008) 199, 33–40fat-burning machines (Rial & Gonzalez-Barroso 2001).
Such a role in energy dissipation could also be inferred
from the effects of UCP2 in glucose-stimulated insulin
secretion. When UCP2 is activated, the pmf falls, the ATP/
ADP ratio diminishes and insulin secretion decreases (Chan
et al. 1999, 2001, Hong et al. 2001). The opposite is also
true. When UCP2 expression decreases, insulin secretion
is enhanced (Zhang et al. 2001, Bordone et al. 2006).
Moreover, genetic studies have identified associations
between polymorphisms in the human UCP2 promoter and
type 2 diabetes as well as decreased insulin secretion (Chan &
Harper 2006). Interestingly, the novel UCP2 inhibitor
genipin also increases insulin secretion (Zhang et al. 2006)
and therefore UCP2 is envisaged as a novel drug target for the
treatment of diabetes. However, whether the main function
of UCP2 in the b-cell is to regulate insulin secretion or to
protect cells from oxidative injury remains a matter of debate
(Produit-Zengaffinen et al. 2007).
White adipose tissue is not only an energy storage site but
also a major endocrine and secretory organ actively involved
in the regulation of energy balance. Defects in adipose tissue
metabolism are one of the links between obesity, insulin
resistance and diabetes. Metformin is a drug used in the
treatment of diabetes but its effects on white adipocyte
metabolism are not fully understood. Metformin does not
influence insulin secretion but rather, it helps to improve the
control of glycaemia by promoting glucose utilization
through an AMPK-mediated stimulation of catabolism
(Bailey et al. 1996, Kirpichnikov et al. 2002). Indeed,
metformin increases lipolysis and reduces triglyceride stores
in adipocytes (Lenhard et al. 1997). Intriguingly, it has also
been reported that AMPK activation inhibits lipolysis and
induces apoptosis (Dagon et al. 2006). The inhibition of the
mitochondrial complex I by metformin supposedly causes an
energy deficit that decreases ATP levels and activates AMPK
(Owen et al. 2000). Additionally, inhibition of complex I is
known to cause an increase in superoxide production
(Turrens 2003). We investigated the effect of metformin on
the adipocyte cell line 3T3-L1 and observed a marked
increase in ROS levels that it is also reflected in a loss of
aconitase activity. These effects support the idea that the
increase in ROS is due to the drug binding to complex I.
Since high ROS levels prompt the response of the cellular
antioxidant defences, the observed increase in UCP2 levels is
consistent with its postulated role in the protection against
oxidative stress. We should also point out that metformin
causes a decrease in total cell mass that can be interpreted as
cell death due to the stress. The increase in UCP2 protein
levels occurs without changes in mRNA, a translational
control of UCP2 expression that has been previously reported
(Pecqueur et al. 2001). The control seems to be exerted by a
36-amino-acid sequence that is coded by an upstream open
reading frame although the intracellular signals involved are
yet to be defined (Hurtaud et al. 2006).
Complex I inhibition could be the primary cause of
AMPK activation although an increase in UCP2 levels couldwww.endocrinology-journals.org
Metformin induces UCP2 in adipocytes . A ANEDDA and others 39also produce the same result. In fact, variations in the
activity/expression of UCP2 in b-cells directly influence the
ATP/ADP ratio and insulin secretion (Affourtit & Brand
2008). Furthermore, ectopic expression of UCP1 in white
adipose tissue decreases the cellular energy content, activates
AMPK and increases lipid oxidation (Matejkova et al. 2004).
We investigated the induction of lipolysis and found a marked
increase in metformin-treated cells although it is only
apparent after a 5-day exposure. While these results are
compatible with UCP2-mediated activation of AMPK, it
must be pointed out that UCP2 levels significantly decreased
by day 12 and, therefore, its presence does not appear to be
required for lipolysis. Our data indicate that the induction of
UCP2 is a direct consequence of metformin-induced
oxidative stress. It is also noteworthy that pharmacological
doses of metformin raise the levels of UCP2 in murine white
adipose tissue, thus providing confirmation of the relevance of
our observations to the in vivo situation. Future work should
be directed towards elucidating whether UCP2 is required to
activate AMPK and to produce the subsequent stimulation of
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